Dr. Fox Discusses Genomic Testing in Breast Cancer

Kevin R. Fox, MD
Published: Friday, Jan 27, 2012

Kevin R. Fox, MD, Medical Director, Rena Rowan Breast Center, University of Pennsylvania, Abramson Cancer Center, discusses the role of genomic testing for women with early-stage breast cancer with positive lymph node status, a concept that is already widely accepted for women that are node-negative.

Women that are estrogen receptor-positive with negative lymph nodes make up the largest minority of patients with early-stage breast cancer. Although the genomic tests are not perfect the results can be used to help determine which chemotherapy treatment should be used.

The success of testing in node-negative cancer has raised the question of whether it should be used in node-positive as well. Despite the limited amount of information the premise is that testing is successful regardless of lymph node status.

Kevin R. Fox, MD, Medical Director, Rena Rowan Breast Center, University of Pennsylvania, Abramson Cancer Center, discusses the role of genomic testing for women with early-stage breast cancer with positive lymph node status, a concept that is already widely accepted for women that are node-negative.

Women that are estrogen receptor-positive with negative lymph nodes make up the largest minority of patients with early-stage breast cancer. Although the genomic tests are not perfect the results can be used to help determine which chemotherapy treatment should be used.

The success of testing in node-negative cancer has raised the question of whether it should be used in node-positive as well. Despite the limited amount of information the premise is that testing is successful regardless of lymph node status.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x